Stock of the Day

April 14, 2021

Genmab A/S (GMAB)

$22.34
-$0.10 (-0.4%)
Market Cap: $14.85B

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Genmab A/S Bull Case

Here are some ways that investors could benefit from investing in Genmab A/S:

  • Recent earnings performance shows promise, with Genmab A/S reporting $0.57 earnings per share, significantly exceeding the consensus estimate of $0.28, indicating strong operational efficiency and potential for growth.
  • The stock is currently trading at $21.30, which may present a buying opportunity for investors looking for value in a company with a solid market capitalization of approximately $14.10 billion.
  • Analysts have a positive outlook, with a "Buy" rating from HC Wainwright and a price target of $50.00, suggesting significant upside potential from the current stock price.
  • Genmab A/S has demonstrated a healthy net margin of 23.49% and a return on equity of 14.64%, indicating effective management and profitability, which are attractive traits for investors.
  • Multiple brokerages have recently upgraded their ratings on Genmab A/S, reflecting growing confidence in the company's future performance and market position.

Genmab A/S Bear Case

Investors should be bearish about investing in Genmab A/S for these reasons:

  • Despite recent earnings beats, the company previously missed analysts' consensus estimates, which could indicate volatility in performance and potential risks in meeting future expectations.
  • The stock has experienced fluctuations, with a one-year low of $18.64, suggesting that it may be subject to market volatility and investor sentiment changes.
  • Analysts' consensus estimate for the current full-year earnings is $1.28 per share, which may not be sufficient to justify the current stock price if growth does not materialize as expected.
  • Genmab A/S has a P/E ratio of 20.68, which, while not excessively high, may indicate that the stock is priced for growth, and any failure to deliver on growth expectations could lead to a decline in stock value.
  • Recent trading volumes have shown variability, with a significant drop in average trading volume, which could suggest reduced investor interest or confidence in the stock.

Recent News